Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis
CONCLUSIONS: The comparative effects of different ESAs on blood transfusions, death (any cause and cardiovascular), major cardiovascular events, myocardial infarction, stroke, vascular access thrombosis, kidney failure, fatigue and breathlessness were uncertain.PMID:36791280 | PMC:PMC9924302 | DOI:10.1002/14651858.CD010590.pub3 (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - February 15, 2023 Category: General Medicine Authors: Edmund Ym Chung Suetonia C Palmer Valeria M Saglimbene Jonathan C Craig Marcello Tonelli Giovanni Fm Strippoli Source Type: research
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis
CONCLUSIONS: The comparative effects of different ESAs on blood transfusions, death (any cause and cardiovascular), major cardiovascular events, myocardial infarction, stroke, vascular access thrombosis, kidney failure, fatigue and breathlessness were uncertain.PMID:36791280 | DOI:10.1002/14651858.CD010590.pub3 (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - February 15, 2023 Category: General Medicine Authors: Edmund Ym Chung Suetonia C Palmer Valeria M Saglimbene Jonathan C Craig Marcello Tonelli Giovanni Fm Strippoli Source Type: research
Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice
Biomed Pharmacother. 2021 Dec 6;146:112502. doi: 10.1016/j.biopha.2021.112502. Online ahead of print.ABSTRACTAntibodies that bind polyethylene glycol (PEG) can be induced by pegylated biomolecules and also exist in a significant fraction of healthy individuals who have never received pegylated medicines. The binding affinity of antibodies against PEG (anti-PEG antibodies) likely varies depending on if they are induced or naturally occurring. Anti-PEG antibodies can accelerate the clearance of pegylated medicines from the circulation, resulting in loss of drug efficacy, but it is unknown how accelerated blood clearance is a...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - December 10, 2021 Category: Drugs & Pharmacology Authors: Tien-Ching Chang Bing-Mae Chen Jer-Yuan Wu Tian-Lu Cheng Steve Roffler Source Type: research
Long-acting erythropoiesis-stimulating agent (ESA) induces physiological erythropoiesis via improvement of iron availability
ConclusionIn this study, we found that anemia treatment with long-acting ESA attenuated the iron utilization for erythropoiesis and maintained target Hb levels without requiring a higher dose of IV iron or ESA. (Source: International Urology and Nephrology)
Source: International Urology and Nephrology - August 14, 2021 Category: Urology & Nephrology Source Type: research
Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial
Conclusions: Oral daprodustat was noninferior to CERA in achieving and maintaining target hemoglobin levels in Japanese ND patients. Daprodustat was well tolerated, with no new safety concerns identified.Am J Nephrol (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - February 9, 2021 Category: Neurology Source Type: research
Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial.
CONCLUSIONS: Oral daprodustat was noninferior to CERA in achieving and maintaining target hemoglobin levels in Japanese ND patients. Daprodustat was well tolerated, with no new safety concerns identified.
PMID: 33561857 [PubMed - as supplied by publisher] (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - February 9, 2021 Category: Urology & Nephrology Authors: Nangaku M, Hamano T, Akizawa T, Tsubakihara Y, Nagai R, Okuda N, Kurata K, Nagakubo T, Jones NP, Endo Y, Cobitz AR Tags: Am J Nephrol Source Type: research
Toward confirmation of the safety and efficacy of methoxy polyethylene glycol-epoetin beta in anemia treatment in patients on hemodialysis: a Macedonian experience.
PMID: 31686463 [PubMed - in process] (Source: Croatian Medical Journal)
Source: Croatian Medical Journal - October 30, 2019 Category: General Medicine Authors: Kacarska-Fotevska I, Volckova N, Ilievska K, Donev D Tags: Croat Med J Source Type: research
Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.
CONCLUSIONS: In patients with anemia of CKD, once-monthly methoxy polyethylene glycol-epoetin beta was noninferior to conventional, shorter-acting erythropoiesis-stimulating agents with respect to rates of major adverse cardiovascular events or all-cause mortality.
PMID: 31420350 [PubMed - as supplied by publisher] (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 15, 2019 Category: Urology & Nephrology Authors: Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB Tags: Clin J Am Soc Nephrol Source Type: research
Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study.
CONCLUSIONS: Data from a real-world setting showed that the adoption of CERA could potentially lead to a reduction in active HCP time.
PMID: 30915883 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 29, 2019 Category: Health Management Tags: J Med Econ Source Type: research
Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study)
ConclusionsThe results suggest that week 12 Hb levels ≥ 11 g/dL achieved with C.E.R.A. treatment were associated with better renal outcomes than Hb levels < 11 g/dL. (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - October 5, 2018 Category: Urology & Nephrology Source Type: research
Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study
Conclusion: A variety of short- and long-acting ESAs are commonly used in European HD facilities to maintain hemoglobin at remarkably similar levels with each ESA type. The availability of numerous ESA options for managing anemia has allowed European providers to optimize anemia management according to the particular circumstances of each patient.Nephron (Source: Nephron)
Source: Nephron - June 26, 2018 Category: Urology & Nephrology Source Type: research
Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
CONCLUSIONS: Using a defined conversion factor, 4-weekly C.E.R.A. was efficacious in maintaining hemoglobin levels in pediatric patients with stable anemia of CKD undergoing hemodialysis, switching from maintenance treatment with epoetin alfa/beta or darbepoetin. Safety was consistent with the known C.E.R.A. safety profile in adults.
PMID: 29097481 [PubMed - as supplied by publisher] (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - November 2, 2017 Category: Urology & Nephrology Authors: Fischbach M, Wühl E, Reigner SCM, Morgan Z, Schaefer F Tags: Clin J Am Soc Nephrol Source Type: research
Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.
CONCLUSIONS: Data from 31 included studies allowed to pool data in meta-analysis related to four different comparisons and eleven outcome measures. Nevertheless, only one result was statistically significant in favor of darbepoetin α in the comparison with epoetin α concerning blood transfusions. For all the other outcomes and comparisons, we did not find any differences in terms of efficacy and security between the EPO considered. The quality of evidence is quite low, and further research could change these results. Further high quality studies examining the comparative effectiveness of ESAs need to be conducted.
...
Source: Journal of Nephrology - June 23, 2017 Category: Urology & Nephrology Authors: Amato L, Addis A, Saulle R, Trotta F, Mitrova Z, Davoli M Tags: J Nephrol Source Type: research
Influence of Erythropoiesis-Stimulating Agents on HbA1c and Fructosamine in Patients with Haemodialysis
Exp Clin Endocrinol Diabetes DOI: 10.1055/s-0042-124577
HbA1c is the most accepted laboratory parameter for the long term observation of glucose control. There is still much of a debate about the use of HbA1c as a metabolic indicator in diabetic patients (DM) on haemodialysis (HD) and erythropoiesis-stimulating agent (ESA) therapy because of the altered erythrocyte turn over in patients with chronic kidney disease and haemodialysis (CKD5D).
In 102 CKD5 patients with and without diabetes mellitus, we examined the dose dependent variability in HbA1c and fructosamine levels under haemodialysis and treated with epoetin α (n=4...
Source: Experimental and Clinical Endocrinology and Diabetes - April 13, 2017 Category: Endocrinology Authors: Rasche, Franz Maximilian Ebert, Thomas Beckmann, Julia Busch, Volker Barinka, Filip Rasche, Wilma Gertrud Lindner, Tom H. Schneider, Jochen G. Schiekofer, Stephan Tags: Article Source Type: research
Methoxy polyethylene glycol-epoetin beta as a novel erythropoiesis stimulating agent with possible nephroprotective and cardiovascular protective effects in non-dialysis chronic kidney disease patients.
Abstract
Chronic kidney disease (CKD) is an important health problem, because of unsuccessful outcomes such as CKD progression to end stage renal disease and high risk of cardiovascular disease (CVD). Anemia, associated with CKD, is considered a non-traditional risk factor for CVD which may contribute to faster CKD progression. Anemia treatment with erythropoiesis-stimulating agents (ESAs) seems to exert non-hematopoietic effects on different tissues and organs, including cardiovascular system and kidneys. On the other hand, clinical use of high doses of short-acting ESAs and higher target hemoglobin level...
Source: Current Pharmaceutical Biotechnology - January 25, 2017 Category: Biotechnology Authors: Piotr B, Mariusz S, Jacek R Tags: Curr Pharm Biotechnol Source Type: research
